FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES (Q2035463): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Changed an Item) |
||
| Property / contained in NUTS | |||
| Property / contained in NUTS: Province of Rome / rank | |||
Normal rank | |||
Revision as of 14:35, 15 July 2020
Project in Italy financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | FOR GENEVAX: FROM GENES TO TRANSNATIONAL VACCINES |
Project in Italy financed by DG Regio |
Statements
186,460.21 Euro
0 references
372,920.43 Euro
0 references
50.0 percent
0 references
14 February 2017
0 references
13 October 2019
0 references
EVVIVAX S.R.L.
0 references
ISTITUTO SUPERIORE DI SANITA'
0 references
41°53'35.95"N, 12°28'58.55"E
0 references
I VACCINI GENETICI HANNO MOLTEPLICI VANTAGGI POTENZIALI, TRA CUI IL TARGETING SPECIFICO, L'USO DI GENI MULTIPLI PER MIGLIORARE L'IMMUNITà , LA VELOCITà DI SINTESI E LA RIDUZIONE DEL RISCHIO RISPETTO AI VACCINI CONVENZIONALI. EVVIVAX Ê UNA NUOVA AZIENDA CH (Italian)
0 references
GENETIC VACCINES HAVE MULTIPLE POTENTIAL BENEFITS, INCLUDING SPECIFIC TARGETING, THE USE OF MULTIPLE GENES TO IMPROVE IMMUNOLOGY, THE SPEED OF SUMMARIES AND THE REDUCTION OF RISK IN RELATION TO CONVENTIONAL VACCINES. EVVIVAX Ê A NEW COMPANY CH (English)
0 references
Identifiers
F89J18000160007
0 references